Company intelligence / Profile preview

BruCells

Gosselies, Wallonia, Belgiumbrussels42.net ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

BruCells develops and manufactures autologous cell therapy products, with a focus on immune cell-based cancer therapies, including dendritic cell vaccines and adoptive T-cell therapies; early clinical data have demonstrated immunogenicity and feasibility, with some reported tumor regression in small clinical or compassionate use contexts.

Therapeutic areas: Oncology
Modalities: Cell therapyAdoptive cell therapyDendritic cell therapy
Industry: Biotech

Drug pipeline

3 assets

Omp19

Pre-clinical

Indications: Brucellosis

2 more assets in the full pipeline.

Request access →

Partnerships

Academic collaborations with Belgian universities (notably Université Libre de Bruxelles, ULB)

Beyond the preview

Go deeper on BruCells.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BruCells.

Explore the full profile